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ABSTRACT 
Renin Angiotensin Aldosterone System (RAAS) plays an important role in the development of hypertension. On 
the other hand, hypertension is a well-known and independent risk factor for cognitive impairment. The aim of the 
present study was to evaluate the relationship of blood pressure control, plasma angiotensin peptides and aldoste-
rone with cognitive functions. Forty-one patients who were under treatment with the same antihypertensive med-
ications for at least three months were included in the study. Plasma angiotensin II, angiotensin 1-7, angiotensin 
IV, and aldosterone concentrations were analyzed using an enzyme-linked immunosorbent assay (ELISA). Stand-
ardized Mini Mental State Examination (SMMSE) was used to evaluate cognitive functions. When the participants 
were grouped according to their SMMSE scores (cut-off value: 26 points), we determined significant differences 
between systolic blood pressure (SBP) levels, diastolic blood pressure levels, plasma angiotensin II and angioten-
sin 1-7 concentrations of the groups. When the participants were stratified according to their SBP levels (cut-off 
value: 140 mm Hg), we found significant differences in SMMSE scores and plasma angiotensin IV concentrations 
of the groups. A negative correlation between SBP and SMMSE scores and strong linear correlations among an-
giotensin peptides levels were determined. The relationship found between SBP and SMMSE in the present study 
was compatible with the literature. Our 33 patients were using at least one angiotensin II receptor blocker (ARB). 
Regarding AT1 receptor blockage, the significant association between higher SMMSE scores and increased angi-
otensin peptides may support a finding that ARBs prevent dementia and improve cognitive function. Further larger 
studies are needed to confirm and prove the relation of RAAS biochemical parameters with cognitive function. 
 
Keywords: hypertension, cognitive functions, angiotensin, aldosterone  
 
 
 
INTRODUCTION 
The prevalence of hypertension is corre-
lated with age, seen in nearly 50 % of individ-
uals aged between 60-69 years and affects ¾ 
of people aged more than 70 years (Burt et al., 
1995). With the increased awareness of hy-
pertension over the last 30-40 years, there has 
been a significant decrease in deaths due to 
cerebrovascular and cardiovascular diseases. 
These data seen in the literature confirm that 
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hypertension is an independent risk factor in 
the development of cerebrovascular and car-
diovascular diseases.  
The renin angiotensin aldosterone system 
(RAAS) plays an important role in the devel-
opment of hypertension. RAAS, being an im-
portant mechanism in electrolyte balance and 
blood pressure regulation, also leads to car-
diac and renal changes via neuronal, hormo-
nal, and metabolic effects. For this reason, 
RAAS blockage is very important for the pre-
vention of hypertension and its complications. 
RAAS is a complicated system with several 
parameters (Figure 1). Each day we acquaint 
ourselves with new insights into the role of 
RAAS in the pathophysiology of cardiovas-
cular disorders (Tusukomato and Kitakaze, 
2013). 
 
 
Figure 1: The renin-angiotensin-aldosterone 
system 
 
The relation between cognitive function 
and hypertension has become a leading area 
of interest in recent years. Independent from 
blood pressure and blood pressure control, 
many studies and reviews have investigated 
the role of RAAS in cognitive function. 
RAAS-blocking antihypertensive drugs af-
fects this complex system from different 
points and thus leads to increased or de-
creased production of different metabolites. 
Due to their effects on RAAS system, the pos-
sible effects of antihypertensive drugs on 
RAAS parameters are listed in Table 1.  
Angiotensin II is the major active media-
tor of RAAS system and most of its effects are 
provided via angiotensin type I (AT1) and 
type II (AT2) receptors. Effects such as vaso-
constriction, aldosterone release, cardiovas-
cular hypertrophy and hyperplasia, catechola-
mine release, and tubular sodium retention is 
provided via AT1 receptor. In addition, AT1 
is responsible in the pathogenesis of athero-
sclerosis and cardiovascular remodeling. In 
general, the AT2 receptor shows antagonistic 
effect when compared with the AT1 receptor 
(Berry et al., 2001). The major effects of an-
giotensin II via the AT2 receptor are apopto-
sis, osmoregulation, cerebral blood flow reg-
ulation, prostaglandin metabolism, angiogen-
esis, nitric oxide release, and vasodilatation 
(Inagami and Senbonmatsu, 2001). 
Angiotensin 1-7 is the most pleiotropic bi-
oactive substance of the RAAS system. Angi-
otensin 1-7 shows its effect via Mas receptors, 
which are coded by Mas proto-oncogenes and 
bound to G proteins. The Mas receptor was 
shown to be a physiologic antagonist to angi-
otensin II’s effect over AT1 (Kostenis et al., 
2005). It has been shown in some studies that 
the underlying reason for the cognitive im-
provements provided by ACE inhibitors   
 
Table 1: Potential effects of antihypertensive drugs on RAAS parameters. *Although CCBs and Diuret-
ics do not have direct effects on the RAAS system, they possibly activate the RAAS system within 
compensator mechanisms. ** Potassium-sparing diuretics antagonize effect of aldosterone. 
 Angiotensin II Angiotensin 1-7 Angiotensin IV Aldosterone 
ACEis ↓ ↑ ↓ ↓ 
ARBs ↑ ↑ ↑ ↓ 
*CCBs ↑ ↑ ↑ ↑ 
*Diuretics ↑ ↑ ↑ ↑↓** 
BBs ↓ ↓ ↓ ↓ 
DRIs  ↓ ↓ ↓ ↓ 
ACEi:  Angiotensin-converting enzyme inhibitor, ARB: Angiotensin II receptor blocker, CCB: Calcium channel blocker, BB: Beta 
blocker, DRI: Direct renin inhibitor 
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might be related with increased angiotensin 1-
7 levels (Tom et al., 2003; Von Bohlen und 
Halbach and Albrecht, 2006).  
Angiotensin IV is a metabolite of angio-
tensin II. Other than angiotensin II receptor 
antagonists (ARB), RAAS-blocking agents 
(ACEi, beta blockers, direct renin inhibitors) 
also block formation of angiotensin II. For 
this reason, RAAS blockers (excluding ARB) 
might also decrease angiotensin IV formation. 
The positive effects of angiotensin IV on cog-
nitive processes such as learning and memory 
have been shown in animal studies (Gard, 
2008). Although it is yet unclear, increased 
angiotensin IV levels may be one of the un-
derlying reasons for cognitive improvement 
provided with ARB use.  
The final metabolite of RAAS, aldoste-
rone, is stimulated by angiotensin II via the 
AT1 receptor. Aldosterone is known to have 
a role in the development of cardiovascular 
diseases such as hypertension, left ventricular 
hypertrophy, heart failure, and renal failure 
(Murin, 2005) 
Cognitive functions can be described as 
learning, memory, planning, organization, 
problem solving, focusing and sustaining at-
tention, understanding the environment, and 
calculation, which reflect the high processing 
capacity of the brain. Hypertension is one of 
the early onset cardiovascular diseases. For 
this reason, hypertension is a good model to 
investigate the effects of systemic and cardio-
vascular diseases on cognitive functions (Na-
tional Research Council (US) Committee on 
Future Directions for Cognitive Research on 
Aging, 2000). For evaluating the cognitive 
functions, we used standardized mini mental 
test (SMMSE) which is a scale for estimating 
the severity of cognitive impairment and 
monitoring the progress.  
In this study, we aimed to investigate the 
relation of plasma angiotensin II, angiotensin 
1-7, angiotensin IV, aldosterone concentra-
tions, and blood pressure with cognitive func-
tions.  
METHODS 
Study population  
Forty-one patients with hypertension who 
were under treatment with the same antihy-
pertensive medications for at least three 
months and presented to Istanbul Medical 
Faculty Department of Clinical Pharmacol-
ogy Polyclinic were included in this cross-
sectional study. The study was approved by 
Istanbul Medical Faculty Clinical Research 
Ethics Committee and enrolled participants 
gave their written informed consent. The in-
clusion and exclusion criteria are listed at Ta-
ble 2. We also evaluated the laboratory test 
results of the patients from the last one month. 
 
Blood pressure measurement 
Blood pressure measurements were done 
after resting for a minimum of 5 minutes in 
the sitting position, measured using a clinical-
trial-use approved, validated, and calibrated 
oscillatory blood pressure measurement de-
vice (Omron 7051T, Kyoto, Japan). The pa-
tients did not take caffeine-containing drinks 
or smoke cigarettes 30 minutes before meas-
urement. Three measurements were taken 
with 5-minute intervals and blood pressure 
level was recorded as the average of those 3 
measurements. We used a systolic blood pres-
sure level of 140 mmHg as a cut-off point. 
 
Biochemical analysis 
Plasma specimens were collected to 
measure plasma angiotensin II, angiotensin 
IV, angiotensin 1-7, and aldosterone levels 
using an enzyme-linked immunosorbent as-
say (ELISA) (Aldosterone ELISA kit - DRG 
international USA; Human Angiotensin 1-7 
ELISA KIT, Human Angiotensin II ELISA 
KIT, and Human Angiotensin 4 ELISA kit- 
Eastbiopharm Co. Ltd Hangzhou, China). All 
specimens were collected between 08:00 and 
10:00 a.m.
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Table 2: Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Written informed consent under no effect 
 Patients with hypertension treated with the 
same antihypertensive medications for at 
least three months  
 Followed up outpatient 
 Patients aged ≥18 years and <80 years 
 Speaking and writing in Turkish - at least 
five years of education 
Exclusion Criteria 
 Any of the below within 12 months of the 
study recruitment date: 
 Myocardial infarction 
 New York Heart Association class II 
through IV chronic heart failure 
 PTCA or CABG surgery 
 2nd or 3rd heart block without pace-
maker or symptomatic arrhythmia 
 Clinically significant heart valve dis-
ease 
 Concomitant life-threating or sympto-
matic arrhythmia 
 Concomitant unstable angina pectoris 
 Atrial fibrillation 
 Uncontrolled diabetes (HbA1C levels 
> 7 %) 
 Cerebrovascular disease history, ischemic 
attack history, encephalopathy 
 Patients with central nervous system dis-
ease and taking medication for this disease 
 Drug/substance abuse in the last 12 
months 
 Significant hepatic disease  
(ALT/AST >2 times ULN) 
 Significant renal disease ( 
GFR < 60 mL/min according to Cockroft-
Gault formula) 
 
 
Patients stayed for 30 minutes in the su-
pine position before their blood was drawn. 
Venous blood samples were collected in 4 mL 
tubes with EDTA for plasma aldosterone 
level measurement. Samples were immedi-
ately centrifuged at 1000 rpm for 15 minutes. 
Venous blood samples for angiotensin pep-
tides were collected in precooled tubes with 
EDTA then immediately centrifuged at 
2000 rpm for 20 minutes at +4 C and plasma 
was directly transported into precooled Ep-
pendorf tubes.  
All samples were stored at -80 C until re-
quired for analysis. All samples were ana-
lyzed in duplicate. 
 
Evaluation of cognitive functions 
In accordance with the Diagnostic and 
Statistical Manual of Mental Disorders (4th 
ed., text rev.; DSM-IV-TR; American Psychi-
atric Association, 2000) criteria (American 
Psychiatric Association, 2000), all patients 
were first interviewed to exclude dementia. 
We used a standardized mini mental test 
(SMMSE) in Turkish, which was validated in 
2002 by Güngen et al. (2002) to evaluate cog-
nitive function. Mental scores were evaluated 
over 30 points. We used an SMMSE score of 
26 points as a cut-off point.  
 
Statistical analysis 
Statistical analyses were performed using 
IBM’s Statistical Package for the Social Sci-
ences (SPSS) for Windows version 21.0. The 
distribution of variables was tested using the 
Shapiro-Wilk test. For variables with normal 
distribution, t-test and Pearson’s correlation 
analysis were performed. For variables with-
out normal distribution, Mann-Whitney U test 
and Spearman’s rho correlation analysis were 
conducted. The results were considered sig-
nificant if p < 0.05. The results of the para-
metric tests are presented as mean ± standard 
deviation and nonparametric tests are pre-
sented as median (25th -75th percentiles). 
 
RESULTS 
Forty-one patients (26 women/15 men, 
mean age 57.41 years (range, 41-69 years) 
were consecutively enrolled in the study. The 
SMMSE scores of the patients resulted with a 
mean of 27.37 ± 2.426. Ten patients with a 
SMMSE score of 26 or lower were considered 
to have cognitive impairment. Twenty pa-
tients with SBP levels of 140 mmHg or higher 
were considered to have uncontrolled hyper-
tension. The antihypertensive medications of 
the patients are summarized at Table 3. 
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Table 3: The Patients’ Antihypertensive Medica-
tions  
Drug Class  Number of  
Patients 
ARB+HCTZ 8 
BB 4 
ARB+HCTZ+BB 3 
ARB+HCTZ+CCB 6 
ARB 6 
ARB+BB 3 
CCB 3 
ARB+CCB 4 
ARB+HCTZ+CCB+BB 1 
BB+CCB 1 
ARB+CCB+BB 2 
Total 41 
ACEi: angiotensin-converting enzyme inhibitor, ARB: angio-
tensin II receptor blocker, CCB: calcium channel blocker, BB: 
beta blocker, HCTZ: hydrochlorothiazide 
 
 
We stratified the patients into two groups 
according to their SMMSE score and SBP 
level. The basic characteristics of the study 
groups were similar and there were no signif-
icant differences. The mean age and years 
since first diagnosis of hypertension of pa-
tients with SMMSE scores of 26 or lower 
were 56.1 ± 5.60 and 8.7 ± 7.66 years, respec-
tively. The mean age and years since first di-
agnosis of hypertension of patients with 
SMMSE scores of 27 or higher were 
57.84 ± 8.36 and 9.01 ± 6.75 years, respec-
tively.  
The mean age and years since first diag-
nosis of hypertension of patients with SBP 
levels of 140 mm Hg or higher were 
58.45 ± 7.37 and 9.53 ± 7.06 years, respec-
tively. The mean age and years since first di-
agnosis of hypertension of patients with SBP 
levels lower than 140 mm Hg were 
56.43 ± 8.15 and 8.37 ± 6.85 years, respec-
tively.  
When participants were grouped as 
SMMSE score > 26 points (n=31) and 
SMMSE score ≤ 26 points (n=10), there were 
significant differences between systolic blood 
pressure (SBP) levels (p < 0.05), diastolic 
blood pressure (DBP) levels (p < 0.01), 
plasma angiotensin II (p < 0.05), and angio-
tensin 1-7 (p < 0.05) concentrations of the 
groups, whereas no significant relationship 
was detected with plasma angiotensin IV and 
aldosterone concentrations (Table 4). 
We stratified the patients according to 
their SBP levels. When participants were 
grouped as SBP ≥ 140 mm Hg (n=20) and 
SBP < 140 mm Hg (n=21), the differences of 
SMMSE scores (p < 0.05) and plasma angio-
tensin IV concentrations (p < 0.05) were 
found significant, whereas no significant rela-
tionship was found with plasma angiotensin 
II, angiotensin 1-7, and aldosterone concen-
trations (Table 5).  
 
 
Table 4: The differences between the groups according to SMMSE scores. The results are presented 
as mean ± standard deviation or median (25th -75th percentiles) according to the statistical test.  
 SSMSE ≤ 26 (n=10) SMMSE > 26 (n=31) p value 
Systolic Blood Pressure 
(mm Hg) 
146.5 ± 9.071 133.77 ± 13.313 p = 0.008 
Diastolic Blood Pres-
sure (mm Hg) 
87.30 ± 8.782 78.32 ± 6.725 p = 0.002 
Plasma Ang II levels 
(ng/mL) 
0.079 (0.067 - 0.098) 0.097 (0.080 - 0.204) p = 0.036 
Plasma Ang 1-7 levels 
(ng/mL) 
0.059 (0.051 - 0.076) 0.086 (0.067 - 0.149) p = 0.034 
Plasma Ang IV  levels 
(ng/mL) 
0.033 (0.021 - 0.069) 0.056 (0.030 - 0.143) p > 0.05 
Plasma Aldosterone 
levels (pg/mL) 
23.098 ± 2.028 23.4373 ± 2.440 p > 0.05 
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Table 5: The differences between the groups according to SBP levels. The results are presented as 
mean ± standard deviation or median (25th -75th percentiles) according to statistical test. SBP: Systolic 
blood pressure 
 SBP ≥140 mm Hg 
(n=20) 
SBP <140 mm Hg 
(n=21) 
p value 
SMMSE score 27.50 (23.25 - 28.75) 28.00 (27.50 - 30.00) p = 0.020 
Plasma Ang II levels 
(ng/mL) 
0.089 (0.076 - 0.105) 0.094 (0.076 - 0.426) p > 0.05 
Plasma Ang 1-7 levels 
(ng/mL) 
0.071 (0.058 - 0.096) 0.095 (0.061 - 0.273) p > 0.05 
Plasma Ang IV  levels 
(ng/mL) 
0.040 (0.023 - 0.062) 0.065 (0.032 - 0.191) p = 0.039 
Plasma Aldosterone 
levels (pg/mL) 
22.9998 ± 2.244 23.6924 ± 2.408 p > 0.05 
 
A negative correlation between SBP and 
SMMSE scores (r = -0.367, p = 0.018), nega-
tive correlations between plasma angiotensin 
IV concentration and SBP (r = -0.385, p = 
0.013), and plasma angiotensin IV concentra-
tion and DBP (r = -0.346, p = 0.027) were de-
tected using correlation analysis. Besides, 
strong linear correlations among angiotensin 
peptides levels were determined. The correla-
tions found in the present study are given in 
Table 6. There was no correlation between 
plasma aldosterone levels and any of the 
study parameters.  
 
DISCUSSION 
The average life span is increasing world-
wide and dementia and cognitive impairment 
incidence is rising in parallel with the aging 
population. It is evident that high blood pres-
sure levels are related with cognitive impair-
ment, stroke, and cerebrovascular diseases. 
Research on the impact of RAAS, which 
plays a critical role in the development of hy-
pertension, is a leading topic in current clini-
cal trials. Although several articles have in-
vestigated the relation between RAAS and 
cognitive functions, it should be further inves-
tigated. 
 
 
 
Table 6: Correlations found in the study. Ang: angiotensin SBP: systolic blood pressure, DBP: diastolic 
blood pressure 
  SMMSE DBP SBP Ang II Ang  
1-7 
Ang IV 
SMMSE Correlation Coefficient - -0.257 -0.367* 0.249 0.184 0.163 
p-value  0.105 0.018 0.116 0.248 0.309 
DBP Correlation Coefficient -0.257 -   0.686** -0.268 -0.149 -0.346* 
p-value 0.105  <0.001 0.091 0.352 0.027 
SBP Correlation Coefficient -0.367* 0.686** - -0.231 -0.224 -0.385* 
p-value 0.018 <0.001  0.146 0.159 0.013 
Ang II Correlation Coefficient 0.249 -0.268 -0.231 - 0.848** 0.766** 
p-value 0.116 0.091 0.146  <0.001 <0.001 
Ang 1-7 Correlation Coefficient 0.184 -0.149 -0.224 0.848** - 0.745** 
p-value 0.248 0.352 0.159 <0.001  <0.001 
Ang IV Correlation Coefficient 0.163 -0.346* -0.385* 0.766** 0.745** - 
p-value 0.309 0.027 0.013 <0.001 <0.001  
*Correlation significant at the 0.05 level, ** Correlation significant at the 0.01 level 
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In our study, patients with high systolic 
blood pressure resulted with low SMMSE 
scores. The negative correlation between sys-
tolic blood pressure and SMMSE shows that 
hypertension is an independent risk factor in 
cognitive impairment. In addition, when pa-
tients were classified as SMMSE ≤ 26 and 
> 26, the difference between the diastolic 
blood pressure levels of the two groups was 
significant (p < 0.005). The importance of 
keeping blood pressure levels under control 
seemed to be important in maintaining cogni-
tive functions in a trial of the elder population 
(Waldstein and Katzel, 2004). 
In research published in 2011, high 
plasma aldosterone levels were shown to be 
associated with cognitive impairment. When 
their results were evaluated in a multiple re-
gression analysis, age (p < 0.001), plasma al-
dosterone concentration (p < 0.001), and cer-
ebral infarction history (p < 0.005) were re-
versely associated with SMMSE scores. Min-
eralo-corticoid receptor blockage was associ-
ated with cognitive impairment prevention as 
well as cardiovascular mortality prevention 
(Yagi et al., 2011). In our study, there was no 
correlation between plasma aldosterone con-
centration and MMSE scores, which may 
have been related with the trial’s design, study 
population and the number of patients.  
Plasma aldosterone and angiotensin con-
centrations might be affected by several fac-
tors such as age, drugs, Na intake, and posture 
of the patient. In our study, patients lied down 
for 30 minutes before their samples were 
taken and they were also informed about Na 
diet. Evaluating sensitive parameters such as 
plasma aldosterone concentrations may be re-
quired with high numbers of samples. Be-
sides, increased aldosterone levels were 
shown to be related with cerebrovascular 
function and intensive antihypertensive treat-
ment may benefit the most for the patients 
with high aldosterone levels (Hajjar et al., 
2015). As a result, prospective studies with 
larger sample sizes are needed to confirm the 
role of aldosterone on cognition.  
Hypertension is related with RAAS acti-
vation and endothelial dysfunction. There-
fore, it can be associated with abnormal regu-
lation of cerebral blood flow and cognitive 
impairment (Hajjar et al., 2009). The role of 
the endothelium in cognitive function, ageing, 
and hypertension has been highlighted (Dal-
Ros et al., 2009; Dimitropoulou et al., 2006; 
Haberl et al., 1991; Hajjar et al., 2009; Khalil 
et al., 2007). Angiotensin II, especially via 
AT1 receptor, impairs endothelial function 
and plays a pathophysiologic role (Ai et al., 
2007; Dal-Ros et al., 2009; Dimitropoulou et 
al., 2006; Haberl et al., 1991; Hajjar et al., 
2009) Although no significant correlation was 
shown between angiotensin II levels and 
SMMSE scores, when the SMMSE score of 
26 was accepted as a threshold, the difference 
between the groups was significant 
(p < 0.05). In the SMMSE > 26 group, angio-
tensin II levels were also high. Considering 
the negative effects created by angiotensin II 
via the AT1 receptor, this could be related to 
most patients’ (n = 33) ARB use. It is known 
that angiotensin II has reverse effects via AT1 
and AT2 receptors. AT1 receptor blockage by 
ARBs increases angiotensin II levels and this 
increased angiotensin II binds to AT2 and 
other receptors, or converted to other ele-
ments of the RAAS system. It is not surpris-
ing to observe that positive SMMSE score re-
sults in patients using ARB with increased an-
giotensin II levels. On the other hand, mid-
products of RAAS that have positive effects 
on cognitive function increase. Angiotensin II 
is also a precursor of several mid-products 
such as the neuroactive angiotensin IV 
(Braszko, 2006). In other respects, a hypothe-
sized mechanism suggested that acetylcholine 
release may be inhibited by angiotensin II and 
stimulation of AT2 receptor can be a neuro-
protective factor (Gorelick and Nyenhuis, 
2012).  
There was no correlation between angio-
tensin 1-7 and SMMSE scores. However, 
when patients were grouped with the SMMSE 
26-point threshold, the difference between 
groups was significant (p < 0.05). Angioten-
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sin 1-7 plays a role in peripheral vasodilata-
tion, diuresis, and antiproliferation via NO, 
kinin and prostaglandin release (Hilchey and 
Bell-Quilley, 1995). In patients treated with 
ACE inhibitors, increased angiotensin 1-7 
levels are claimed to be related with cognitive 
function improvement (Tom et al., 2003; Von 
Bohlen und Halbach and Albrecht, 2006). 
Although the difference between the ACEi 
and ARBs is yet unclear, angiotensin 1-7 lev-
els also increase with an ARB treatment 
(Schindler et al., 2007). 
Among all biochemical parameters, the 
role of angiotensin IV in RAAS was the least 
clarified. In the present study, plasma angio-
tensin IV levels of SMMSE > 26 group were 
higher than plasma angiotensin IV levels of 
SMMSE ≤ 26 group but this difference did 
not reach a statistically significant level. 
Stimulation of the AT4 receptor had a posi-
tive effect on cognitive effects such as 
memory and learning in animal studies that 
administered angiotensin IV (Albiston et al., 
2004; Braszko, 2004; Lee et al., 2004; Gard, 
2008). Although it is too early to come to a 
conclusion, the cognitive improvement pro-
vided by ARBs could be related with angio-
tensin IV. Animal studies showed angiotensin 
IV had positive effects on cognitive functions. 
In the present study, there was no correlation 
between MMSE scores and angiotensin IV 
concentrations. A possible explanation for 
this is that angiotensin-specific receptors are 
mostly found in the brain and show their ef-
fects via the local RAAS. Prospective trials 
are needed to document the effect of angio-
tensin IV on cognitive processes. 
One of the remarkable results in our study 
was that there was no correlation between 
blood pressure and angiotensin 1-7 or angio-
tensin II, but angiotensin IV levels were in-
versely correlated with both systolic and dias-
tolic blood pressure (p < 0.005). Angiotensin 
IV is mostly localized in the brain and inter-
acts with AT1 and AT2 receptors as well as 
AT4 (Capponi and Catt, 1979; Handa et al., 
1999; Le et al., 2002). In a rat trial, angioten-
sin IV administered as i.v. bolus increased ar-
terial blood pressure, this effect was pre-
vented by AT1 blockage (Yang et al., 2008). 
Angiotensin IV might stimulate AT1 recep-
tors in the brain and increase sympathetic out-
flow and blood pressure (Lochard et al., 
2004). Some effects caused by angiotensin IV 
are believed to be through AT1 receptor stim-
ulation (Fitzgerald et al., 1999; Gardiner et 
al., 1993; Yang et al., 2008). In the present 
study, the negative correlation between angi-
otensin IV and blood pressure was in contrast 
to this information; however, it should be kept 
in mind that 33 of our cases were treated with 
at least one ARB. In this condition, angioten-
sin IV might not show the effects via AT1 re-
ceptor. In other respects, Spearman’s rho cor-
relation analysis showed a strong linear corre-
lation between angiotensin II and IV (r = 
0.766, p < 0.001), angiotensin II and angio-
tensin 1-7 (r = 0.848, p < 0.001), and angio-
tensin 1-7 and angiotensin IV (r = 0.745, 
p < 0.001). Considering that angiotensin 1-7 
and angiotensin IV are mid-products of 
RAAS, these correlations are expected result. 
In this sense, negative correlation between an-
giotensin IV and systolic blood pressure 
might also be explained as angiotensin II’s 
and angiotensin IV’s effects via AT2 receptor 
and vasodilator effect of angiotensin 1-7. 
 
CONCLUSIONS 
Compatible with previous findings, inde-
pendent of antihypertensive-type medica-
tions, keeping blood pressure under control to 
prevent cognitive impairment is one of the 
important results of the present study.  
Although the present study has a small 
sample size for arriving at a definite conclu-
sion, our research may support such a hypoth-
esis that system needs to work and increase in 
angiotensin peptides levels may be associated 
with better cognitive functions. In other re-
spects, with the exception of the negative ef-
fects of angiotensin II on AT1 receptors and 
high plasma aldosterone levels, the latest 
findings in this field support that RAAS prod-
ucts and mid-products may have some addi-
tional beneficial effects on cognition. ARBs 
are the only antihypertensive drug group that 
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increase all angiotensin peptides and block 
AT1 receptors. For this reason, ARBs may 
provide additional benefit in cognition due to 
their effects on RAAS. The present study sup-
ports this finding. In our study it was not pos-
sible to compare ARBs and other antihyper-
tensive drugs because all of the patients in our 
study were using very different medications. 
Further larger prospective studies are needed 
to understand and prove the relation of RAAS 
biochemical parameters with cognitive func-
tion. Future studies should be conducted to 
evaluate the same parameters pre and post 
treatment. 
There are no guidelines for the choice of 
antihypertensive drugs for patients with hy-
pertension and cognitive impairment, or to 
prevent cognitive impairment in patients with 
hypertension. Antihypertensive drugs target 
several points on the RAAS pathway, thus 
they increase or decrease different metabo-
lites. As shown in Table 1, four RAAS param-
eters that might be related with cognitive 
function are affected differently by antihyper-
tensive drugs. In addition to intensive man-
agement of blood pressure, it is believed that 
if the relation between RAAS parameters and 
cognitive functions is clarified, there may be 
an opportunity for selecting antihypertensive 
drugs or deciding antihypertensive treatment 
strategies. For the time being, further larger 
prospective studies are still needed to eluci-
date the relation of RAAS biochemical pa-
rameters with cognitive functions.  
 
Limitations 
Although we were very careful and sensi-
tive to follow instructions for storage and cold 
chain, angiotensin levels were measured in 
blood collected in pre-chilled tubes with 
EDTA (as a proteinase inhibitor) that con-
tained no other proteinase inhibitors and 
plasma samples were not extracted, which 
may have limited our study because it may 
have decreased peptide degradation. We used 
tubes with EDTA and performed very strict 
cold chain to keep the peptide degradation to 
a minimum. 
The present study has a small sample size. 
Nevertheless; our study can be considered as 
a pilot study and we found some significant 
findings that may be useful for further larger 
studies.  
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